651 related articles for article (PubMed ID: 33461019)
1. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.
Oz M; Lorke DE
Biomed Pharmacother; 2021 Apr; 136():111193. PubMed ID: 33461019
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
3. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.
Aleksova A; Gagno G; Sinagra G; Beltrami AP; Janjusevic M; Ippolito G; Zumla A; Fluca AL; Ferro F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926110
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
5. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
6. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury.
Yamaguchi T; Hoshizaki M; Minato T; Nirasawa S; Asaka MN; Niiyama M; Imai M; Uda A; Chan JF; Takahashi S; An J; Saku A; Nukiwa R; Utsumi D; Kiso M; Yasuhara A; Poon VK; Chan CC; Fujino Y; Motoyama S; Nagata S; Penninger JM; Kamada H; Yuen KY; Kamitani W; Maeda K; Kawaoka Y; Yasutomi Y; Imai Y; Kuba K
Nat Commun; 2021 Nov; 12(1):6791. PubMed ID: 34815389
[TBL] [Abstract][Full Text] [Related]
7. ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review.
Qu L; Chen C; Yin T; Fang Q; Hong Z; Zhou R; Tang H; Dong H
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768911
[TBL] [Abstract][Full Text] [Related]
8. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2.
Elrashdy F; Redwan EM; Uversky VN
Infect Genet Evol; 2020 Nov; 85():104510. PubMed ID: 32853823
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
Hu Y; Liu L; Lu X
Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
[TBL] [Abstract][Full Text] [Related]
11. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms.
Xu B; Li G; Guo J; Ikezoe T; Kasirajan K; Zhao S; Dalman RL
J Vasc Surg; 2021 Nov; 74(5):1740-1751. PubMed ID: 33600934
[TBL] [Abstract][Full Text] [Related]
13. Origin and genomic characteristics of SARS-CoV-2 and its interaction with angiotensin converting enzyme type 2 receptors, focusing on the gastrointestinal tract.
Galanopoulos M; Doukatas A; Gazouli M
World J Gastroenterol; 2020 Nov; 26(41):6335-6345. PubMed ID: 33244196
[TBL] [Abstract][Full Text] [Related]
14. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
15. Receptor utilization of angiotensin-converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV.
Wang Q; Qiu Y; Li JY; Liao CH; Zhou ZJ; Ge XY
Transbound Emerg Dis; 2021 May; 68(3):1046-1053. PubMed ID: 32794346
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases.
Sharma RK; Li J; Krishnan S; Richards EM; Raizada MK; Mohandas R
Clin Sci (Lond); 2021 Jan; 135(1):1-17. PubMed ID: 33399851
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system at the interface of COVID-19 infection.
Gul R; Kim UH; Alfadda AA
Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029
[TBL] [Abstract][Full Text] [Related]
18. Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes.
Guney C; Akar F
J Pharm Pharm Sci; 2021; 24():84-93. PubMed ID: 33626315
[TBL] [Abstract][Full Text] [Related]
19. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.
Suh SH; Ma SK; Kim SW; Bae EH
Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
